Volume 31 Issue 3-4, March 2024

Cover Credit: AAV-mediated gene therapy for hereditary hearing loss is transitioning from basic research to clinical application. The biodistribution of different AAV vectors after inner ear injection is crucial for researchers to select appropriate serotypes with targeted capabilities while decreasing non-target expression. The image shows the brain transduction of AAV1, AAV2, Anc80L65, AAV9, AAV-PHP.B, and AAV-PHP.eB after round window membrane (RWM) delivery at neonatal mice.